BioCryst Pharmaceuticals, Inc. (BCRX)
7.59
+0.02
(+0.26%)
USD |
NASDAQ |
Dec 15, 16:00
7.49
-0.10
(-1.32%)
After-Hours: 04:22
BioCryst Pharmaceuticals Research and Development Expense (TTM): 173.40M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Astria Therapeutics, Inc. | 98.04M |
| Johnson & Johnson | 15.77B |
| Viatris, Inc. | 886.70M |
| KalVista Pharmaceuticals, Inc. | 55.64M |
| Novavax, Inc. | 369.02M |